Items Tagged ‘postmenopausal’

June 7th, 2016

Treatment with Aromatase Inhibitors for 10 Years Improves Cancer-Free Survival in Breast Cancer

By

Among postmenopausal women with hormone-positive, early breast cancer, treatment with aromatase inhibitors (AIs) for 10 years significantly improves cancer-free survival, compared to the 5-year standard length of AI treatment.  However, quality of life issues, bone density concerns, and a patient’s risk of a recurrence should be taken into consideration to determine the optimal length of […]

View full entry

Tags: AIs, aromatase inhibitors, Breast Cancer, early-stage, hormone-positive, HR+, News, postmenopausal, Stage I Node Negative Breast Cancer, survival


February 27th, 2015

Palbociclib/Letrozole Improves Outcomes of Estrogen Receptor–Positive/HER2-Negative Advanced Breast Cancer

By

The results of the phase II PALOMA-1/TRIO-18 trial were recently reported in The Lancet Oncology and suggest that the addition of Ibrance® (palbociclib) to Femara® (letrozole) delayed the time to cancer progression when used as first-line treatment for advanced breast cancer in postmenopausal women with estrogen receptor (ER)–positive/human epidermal growth factor receptor 2 (HER2)-negative disease. […]

View full entry

Tags: Breast Cancer, ER-positive, estrogen receptor-positive, Femara, HER-2 negative, human epidermal growth factor receptor-negative, Ibrance, kinase inhibitor, letrozole, Metastatic Breast Cancer, News, palbociclib